Fig. 1
From: Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden
Survival analysis of melanoma patients based on PD-L1 expression levels and mutational burden. a, b Overall survival upon stratification based on PD-L1 positivity (tumor proportion score ≥ 1% versus < 1%) for metastatic melanoma patients treated (a) prior to the introduction of ICIs (historical controls; n = 94) and (b) ICI-treated melanoma patients (n = 137). c, d Overall survival upon stratification based on mutational burden [high (≥ 7.1 mut/Mb) versus non-high] for metastatic melanoma patients treated (c) prior to the introduction of ICIs (historical controls; n = 94) and (d) ICI-treated melanoma patients (n = 137). p-values are indicated